Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer

#1817

Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.

Aim(s): To assess the biodistribution and present reasonable estimates of normal organ doses to liver, spleen and kidneys using 177 Lu-DOTATATE and Capecitabine.

Materials and methods: Fifteen patients (mean age 51.4y) of metastatic gastric-intestinal NETs diagnosed with 68Ga-DOTANOC PET-CT,histopathology and biochemical markers were were prescribed oral tablet capecitabine in dose of 500mg/m2 twice daily for 14 days, commencing 9 days prior to PRRT. 6.66 to 7.4 GBq (180-200 mCi) of 177Lu-DOTATATE was infused to each patient with co-infusion of amino acid solution for renal protection. Each patient underwent whole-body scans at 2, 24 and 96 hours post therapy. The organs included in dosimetry were kidney, liver, spleen and tumor sites. All calculations were done using HERMES software

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Dureja S

Authors: Dureja S, Thakral P, Pant V, Pallavi U, Vindhya M,

Keywords: PRRT, radiosensitizer,